The TRAIN-HEART consortium, funded by the European Commission (2019-2023), is made up to train a league of 15 promising fellows that harness novel insights in the pathogenesis of ischemic heart failure, study the therapeutic potential of existing RNA therapeutics and improve its efficacy by the design of novel drug delivery systems.
TRAIN-HEART brings together leading academic teams and (biotech) companies covering various disciplines ranging from fundamental research to clinical pharmacology and gene therapy to drug delivery applications, have teamed up in the European Union.
The TRAIN-HEART network aims to gain viable insight in the pathogenesis of ischemic heart failure which will serve as a basis for drug discovery and drug delivery efforts that aim to therapeutically target specific molecules and mechanisms within cardiomyocytes for the treatment of ischemic heart failure.
If you have any questions you can fill in the form or mail us directly: info@train-heart.eu.
News
From 20 to 24 January 2020 the first TRAIN-HEART network meeting was organized at the Technical University Munchen (Germany) was over 40 participants.
On Monday and Tuesday, all Principal Investigators and ESRs presented their work, research laboratories and project outlines. With true Bayerisches Abendessen and a pleasant guided walk through the center of Munich, also informal connections were established. From Wednesday to Friday, the students participated in a outreach skills training: "How to write and present research projects and results to different audiences" in which subjects such as "Body language & tone of speech" and "Writing effective paragraphs" were addressed. As a final assignment, the students were asked to develop educative video tutorials to present the TRAIN-HEART programme and its research directions to the general public.
Wed, 25 September
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement no. 813716.
Copyright © 2020
